The nation’s leading doctors groups are in a standoff with federal health officials over vaccines. The conflict intensified ...

Merck’s MRK stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, ...

Two new Cochrane reviews by UK researchers provide strong, consistent evidence that human papillomavirus (HPV) vaccination ...

Hundreds of studies, including gold-standard clinical trials, challenge Health Secretary Robert F. Kennedy Jr.’s claim that ...

Merck MRK continues to face challenges with Gardasil, its second-largest product, which is a vaccine approved for the prevention of certain cancers caused by human papillomavirus. Though the vaccine’s ...

Merck’s MRK second-largest product Gardasil is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). Though the vaccine’s sales were consistently rising till 2022, it ...

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck & Co. Inc. (NYSE:MRK) is the ...

Merck to pause China Gardasil shipments through at least the end of 2025 Co expects $3 bln annual savings by end of 2027 Keytruda sales rise 9% to just under $8 billion July 29 (Reuters) - Merck ...

Despite indications that a single dose of Merck's (NYSE:MRK) human papillomavirus vaccine Gardasil could be as effective as the current multi-dosing schedule, the drugmaker said that an alternative ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of the ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. Stream NBC 5 for free, ...

Merck MRK-N said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year forecast and ...